| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
|
Lancet
|
2011
|
4.73
|
|
2
|
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
|
J Clin Oncol
|
2007
|
4.23
|
|
3
|
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2005
|
2.47
|
|
4
|
Breast cancer methylomes establish an epigenomic foundation for metastasis.
|
Sci Transl Med
|
2011
|
2.33
|
|
5
|
Microenvironmental regulation of epithelial-mesenchymal transitions in cancer.
|
Cancer Res
|
2012
|
2.00
|
|
6
|
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
|
J Clin Oncol
|
2007
|
1.93
|
|
7
|
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2006
|
1.64
|
|
8
|
Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition.
|
Cancer Res
|
2012
|
1.57
|
|
9
|
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2009
|
1.53
|
|
10
|
Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
|
Clin Breast Cancer
|
2010
|
1.41
|
|
11
|
Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.
|
Support Care Cancer
|
2004
|
1.29
|
|
12
|
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2007
|
1.28
|
|
13
|
Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration.
|
Cancer Cell
|
2013
|
1.14
|
|
14
|
Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer.
|
Breast Cancer Res Treat
|
2007
|
1.11
|
|
15
|
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
|
Breast Cancer Res Treat
|
2010
|
1.05
|
|
16
|
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
|
Breast Cancer Res Treat
|
2014
|
1.05
|
|
17
|
Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies.
|
Support Cancer Ther
|
2004
|
0.95
|
|
18
|
Eribulin mesylate.
|
Clin Cancer Res
|
2011
|
0.93
|
|
19
|
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
|
Oncologist
|
2014
|
0.89
|
|
20
|
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
|
Breast Cancer Res Treat
|
2011
|
0.86
|
|
21
|
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.
|
Lab Chip
|
2013
|
0.84
|
|
22
|
Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.
|
Breast Cancer Res Treat
|
2010
|
0.82
|
|
23
|
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
|
Clin Cancer Res
|
2013
|
0.82
|
|
24
|
The effect of a contemplative self-healing program on quality of life in women with breast and gynecologic cancers.
|
Altern Ther Health Med
|
2010
|
0.82
|
|
25
|
Epothilones: clinical update and future directions.
|
Oncology (Williston Park)
|
2008
|
0.82
|
|
26
|
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
|
Expert Opin Biol Ther
|
2012
|
0.80
|
|
27
|
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
|
Breast Cancer Res Treat
|
2013
|
0.79
|
|
28
|
New developments in metastatic breast cancer: general discussion.
|
Clin Adv Hematol Oncol
|
2013
|
0.77
|
|
29
|
Eribulin mesylate for the treatment of breast cancer.
|
Expert Opin Pharmacother
|
2010
|
0.77
|
|
30
|
Novel treatment options in the management of metastatic breast cancer.
|
Clin Adv Hematol Oncol
|
2011
|
0.76
|
|
31
|
High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.
|
J Clin Oncol
|
2013
|
0.75
|
|
32
|
New developments in metastatic breast cancer: integrating recent data into clinical practice.
|
Clin Adv Hematol Oncol
|
2013
|
0.75
|
|
33
|
BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
|
Breast Cancer Res Treat
|
2013
|
0.75
|